Price range: $268.00 through $328.00
Background:Enables N6-methyladenosine-containing RNA binding activity and ribosome binding activity. Involved in mRNA destabilization; positive regulation of translational initiation; and stress granule assembly. Located in P-body and cytoplasmic stress granule. [provided by Alliance of Genome Resources, Apr 2022]
| Size | 50μL/100μL |
| Target | YTHDF1 |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IHC, IF, IP, ELISA |
| MW(Calculated) | 61kD |
| MW(Observed) | 70kD |
| Host Species | Rabbit |
| Isotype | IgG,Kappa |
| Conjugate/Modification | Unmodified |
| Recommended Dilution Ratio | IHC 1:200-1:1000; WB 1:1000-1:5000; IF 1:200-1:1000; ELISA 1:5000-1:20000; IP 1:50-1:200, / Note: For IHC, we suggest antigen retrieval with TE buffer pH 9.0 (Cat#WT1004) |
| Formulation | PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA |
| Purification | Recombinant Antibody expressed in animal component-free (ACF) media, purified via Protein A affinity chromatography. |
| Storage | -15°C to -25°C/1 year(Do not lower than -25°C) |
| Concentration | |
| Clonality | Monoclonal |
| Clone Number | RM0326R |
| Immunogen | The specific immunogen used to produce this antibody is proprietary information. |
| Specificity | Endogenous |
| Gene Name | YTHDF1 |
| Protein Name | YTH domain family protein 1 |
| Other Name | C20orf21; / DACA 1; / DACA-1; / Dermatomyositis associated with cancer putative autoantigen 1; / YTH domain family 1; / YTH domain family member 1; / YTH domain family protein 1; / YTHD1; / YTHD1_HUMAN; / Ythdf1 |
| Species | Human |
| Gene ID | 54915 |
| Uniprot | Q9BYJ9, |
| Species.1 | Mouse |
| Gene ID.1 | 228994 |
| Uniprot.1 | P59326 |
| Species.2 | |
| Gene ID.2 | |
| Uniprot.2 | |
| Cellular Localization | Cytoplasm |
| Tissue Expression | In brain, preferentially expressed in the hippocampus. {ECO:0000269|PubMed:30401835}. |
| Signaling_pathway | |
| Research Areas | |
| Function | Specifically recognizes and binds N6-methyladenosine (m6A)-containing mRNAs, and regulates their stability (PubMed:30401835, PubMed:32943573). M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing (PubMed:30401835, PubMed:32943573). Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex (By similarity). The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) share m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation (PubMed:32943573). Required to facilitate learning and memory formation in the hippocampus by binding to m6A-containing neuronal mRNAs (PubMed:30401835). Acts as a regulator of axon guidance by binding to m6A-containing ROBO3 transcripts (PubMed:30843071). Acts as a negative regulator of antigen cross-presentation in myeloid dendritic cells (PubMed:30728504). In the context of tumorigenesis, negative regulation of antigen cross-presentation limits the anti-tumor response by reducing efficiency of tumor-antigen cross-presentation (PubMed:30728504). Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation (By similarity). The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules (By similarity). |
